1,3-Butadiene, a colorless gas regularly used in the production of plastics, thermoplastic resins, and styrene-butadiene rubber, poses an increased leukemia mortality risk to workers in this field. 1,3-Butadiene is also produced by incomplete combustion of motor fuels or by tobacco smoking. It is absorbed principally through the respiratory system and metabolized by several enzymes rendering 1,2:3,4-diepoxybutane (DEB), which has the highest genotoxic potency of all metabolites of 1,3-butadiene. DEB is considered a carcinogen mainly due to its high potential as clastogen, which induces structural chromosome aberrations such as sister chromatid exchanges, chromosomal breaks, and micronuclei. Due to its clastogenic effect, DEB is one of the most used agents for diagnostic studies of Fanconi anemia, a recessively inherited disease related to mutations affecting several genes involved in a common DNA repair pathway. When performing Fanconi anemia diagnostic tests in our laboratory, we have observed occasional multipolar mitosis (MM) in lymphocyte cultures exposed to 0.1 μg/ml of DEB and harvested in the absence of any mitotic spindle inhibitor. Although previous studies reported an aneugenic effect (i.e. it induces aneuploidy) of DEB, no mechanism was suggested to explain such observations. Therefore, the aim of this study was to investigate whether exposure to 0.1 μg/ml of DEB is significantly associated with the occurrence of MM. We blindly assessed the frequency of MM in lymphocyte cultures from 10 nonsmoking healthy individuals. Two series of 3 cultures were performed from each sample under different conditions: A, without DEB; B, with 0.1 μg/ml of DEB, and C, with 25 μM of mitomycin C as positive control. Cultures exposed to DEB showed higher frequencies of MM (23 of 2,000 cells) than did the unexposed ones (3 of 2,000 cells).

1.
Abdel-Rahman SZ, Ammenheuser MM, Ward JB Jr: Human sensitivity to 1,3-butadiene: role of microsomal epoxide hydrolase polymorphisms. Carcinogenesis 22:415-423 (2001).
2.
Abdel-Rahman SZ, Ammenheuser MM, Omiecinski CJ, Wickliffe JK, Rosenblatt JI, Ward JB Jr: Variability in human sensitivity to 1,3-butadiene: influence of polymorphisms in the 5′-flanking region of the microsomal epoxide hydrolase gene (EPHX1). Toxicol Sci 85:624-631 (2005).
3.
Auerbach AD: A test for Fanconi's anemia. Blood 72:366-367 (1988).
4.
Auerbach AD: Diagnosis of Fanconi anemia by diepoxybutane analysis. Curr Protoc Hum Genet 8:8.7 (2003).
5.
Auerbach AD: Fanconi anemia and its diagnosis. Mutat Res 668:4-10 (2009).
6.
Auerbach AD: Diagnosis of Fanconi anemia by diepoxybutane analysis. Curr Protoc Hum Genet 85:8.7.1-8.7.17 (2015).
7.
Auerbach AD, Rogatko A, Schroeder-Kurth TM: International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood 73:391-396 (1989).
8.
Benn PA, Tantravahi U: Chromosome staining and banding techniques; in Rooney DE (ed): Human Cytogenetics: Constitutional Analysis, ed 3, pp 99-128 (Oxford University Press, Oxford 2001).
9.
Bukvic N, Lovreglio P, Fanelli M, Susca FC, Ballini A, et al: Influence of some detoxification enzyme polymorphisms on cytogenetic biomarkers between individuals exposed to very low doses of 1,3-butadiene. J Occup Environ Med 51:811-821 (2009).
10.
Castella M, Pujol R, Callén E, Ramírez MJ, Casado JA, et al: Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact. J Med Genet 48:242-250 (2011).
11.
Chae S, Yun C, Um H, Lee JH, Cho H: Centrosome amplification and multinuclear phenotypes are induced by hydrogen peroxide. Exp Mol Med 37:482-487 (2005).
12.
Cirkovic S, Guc-Scekic M, Vujic D, Ilic N, Micic D, et al: Diagnosis of Fanconi's anemia by diepoxybutane analysis in children from Serbia. Balkan J Med Genet 14:65-70 (2011).
13.
Costa M, Zhitkovich A, Harris M, Paustenbach D, Gargas M: DNA-protein cross-links produced by various chemicals in cultured human lymphoma cells. J Toxicol Environ Health 50:433-449 (1997).
14.
Dong H, Nebert DW, Bruford EA, Thompson DC, Joenje H, Vasiliou V: Update of the human and mouse Fanconi anemia genes. Hum Genomics 9:32 (2015).
15.
Dong J, Wang Z, Zou P, Zhang G, Dong X, et al: Induction of DNA damage and G2 cell cycle arrest by diepoxybutane through the activation of the Chk1-dependent pathway in mouse germ cells. Chem Res Toxicol 28:518-531 (2015).
16.
Duesberg P, Li R, Rasnick D, Rausch C, Willer A, et al: Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet 119:83-93 (2000).
17.
Fabiani R, Rosignoli P, De Bartolomeo A, Fuccelli R, Morozzi G: Genotoxicity of alkene epoxides in human peripheral blood mononuclear cells and HL60 leukaemia cells evaluated with the comet assay. Mutat Res 747:1-6 (2012).
18.
Fletcher L, Muschel RJ: The centrosome and the DNA damage induced checkpoint. Cancer Lett 243:1-8 (2006).
19.
Fustinoni S, Soleo L, Warholm M, Begemann P, Rannug A, et al: Influence of metabolic genotypes on biomarkers of exposure to 1,3-butadiene in humans. Cancer Epidemiol Biomarkers Prev 11:1082-1090 (2002).
20.
Ganem NJ, Pellman D: Linking abnormal mitosis to the acquisition of DNA damage. J Cell Biol 199:871-881 (2012).
21.
Gisselsson D, Hakanson U, Stoller P, Marti D, Jin Y, et al: When the genome plays dice: circumvention of the spindle assembly checkpoint and near-random chromosome segregation in multipolar cancer cell mitoses. PLoS One 3:e1871 (2008).
22.
Grillo CA, Dulout FN: Cytogenetic evaluation of butylated hydroxytoluene. Mutat Res 345:73-78 (1995).
23.
Hlinka D, Kaľatová B, Uhrinová I, Dolinská S, Rutarová J, et al: Time-lapse cleavage rating predicts human embryo viability. Physiol Res 61:513-525 (2012).
24.
Howell RT: Chromosome instability syndromes; in Rooney DE (ed): Human Cytogenetics: Malignancy and Acquired Abnormalities, ed 3, pp 227-254 (Oxford University Press, Oxford 2001).
25.
Hut HM, Lemstra W, Blaauw EH, van Cappellen GW, Kampinga HH, Sibon OC: Centrosomes split in the presence of impaired DNA integrity during mitosis. Mol Biol Cell 14:1993-2004 (2003).
26.
Kalatova B, Jesenska R, Hlinka D, Dudas M: Tripolar mitosis in human cells and embryos: occurrence, pathophysiology and medical implications. Acta Histochem 117:111-125 (2015).
27.
Karna P, Rida PC, Pannu V, Gupta KK, Dalton WB, et al: A novel microtubule-modulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering. Cell Death Differ 18:632-644 (2011).
28.
Kirman CR, Albertini RJ, Sweeney LM, Gargas ML: 1,3-Butadiene: I. Review of metabolism and the implications to human health risk assessment. Crit Rev Toxicol 40(suppl 1):1-11 (2010).
29.
Klisch K, Pfarrer C, Schuler G, Hoffmann B, Leiser R: Tripolar acytokinetic mitosis and formation of feto-maternal syncytia in the bovine placentome: different modes of the generation of multinuclear cells. Anat Embryol (Berl) 200:229-237 (1999).
30.
Korkina LG, Deeva IB, De Biase A, Iaccarino M, Oral R, et al: Redox-dependent toxicity of diepoxybutane and mitomycin C in sea urchin embryogenesis. Carcinogenesis 21:213-220 (2000).
31.
Krause RJ, Elfarra AA: Oxidation of butadiene monoxide to meso- and (±)-diepoxybutane by cDNA-expressed human cytochrome P450s and by mouse, rat, and human liver microsomes: evidence for preferential hydration of meso-diepoxybutane in rat and human liver microsomes. Arch Biochem Biophys 337:176-184 (1997).
32.
Loncarek J, Khodjakov A: Ab ovo or de novo? Mechanisms of centriole duplication. Mol Cells 27:135-142 (2009).
33.
Loncarek J, Hergert P, Magidson V, Khodjakov A: Control of daughter centriole formation by the pericentriolar material. Nat Cell Biol 10:322-328 (2008).
34.
Maiato H, Logarinho E: Mitotic spindle multipolarity without centrosome amplification. Nat Cell Biol 16:386-394 (2014).
35.
Martin GM, Sprague CA: Vinblastine induces multipolar mitoses in tetraploid human cells. Exp Cell Res 63:466-467 (1970).
36.
Murg MN, Schuler M, Eastmond DA: Evaluation of micronuclei and chromosomal breakage in the 1cen-q12 region by the butadiene metabolites epoxybutene and diepoxybutane in cultured human lymphocytes. Mutagenesis 14:541-546 (1999).
37.
Pagano G, Degan P, De Biase A, Iaccarino M, Warnau M: Diepoxybutane and mitomycin C toxicity is associated with the induction of oxidative DNA damage in sea urchin embryos. Hum Exp Toxicol 20:651-655 (2001).
38.
Parry EM, Parry JM, Corso C, Doherty A, Haddad F, et al: Detection and characterization of mechanisms of action of aneugenic chemicals. Mutagenesis 17:509-521 (2002).
39.
Pfau SJ, Amon A: Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep 13:515-527 (2012).
40.
Pihan GA: Centrosome dysfunction contributes to chromosome instability, chromoanagenesis, and genome reprograming in cancer. Front Oncol 3:277 (2013).
41.
Ponte F, Carvalho F, Porto B: Protective effect of acetyl-l-carnitine and α-lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes. Toxicology 289:52-58 (2011).
42.
Ranaldi R, Bassani B, Pacchierotti F: Genotoxic effects of butadiene in mouse lung cells detected by an ex vivo micronucleus test. Mutat Res 491:81-85 (2001).
43.
Recio L, Steen AM, Pluta LJ, Meyer KG, Saranko CJ: Mutational spectrum of 1,3-butadiene and metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane to assess mutagenic mechanisms. Chem Biol Interact 135-136:325-341 (2001).
44.
Ruppitsch W, Meisslitzer C, Hirsch-Kauffmann M, Schweiger M: Overexpression of thioredoxin in Fanconi anemia fibroblasts prevents the cytotoxic and DNA damaging effect of mitomycin C and diepoxybutane. FEBS Lett 422:99-102 (1998).
45.
Seaton MJ, Follansbee MH, Bond JA: Oxidation of 1,2-epoxy-3-butene to 1,2:3,4-diepoxybutane by cDNA-expressed human cytochromes P450 2E1 and 3A4 and human, mouse and rat liver microsomes. Carcinogenesis 16:2287-2293 (1995).
46.
Sellitto C, Kuriyama R: Distribution of pericentriolar material in multipolar spindles induced by colcemid treatment in Chinese hamster ovary cells. J Cell Sci 89:57-65 (1988).
47.
Seyschab H, Friedl R, Sun Y, Schindler D, Hoehn H, et al: Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood 85:2233-2237 (1995).
48.
Stephanou G, Andrianopoulos C, Vlastos D, Demopoulos NA, Russo A: Induction of micronuclei and sister chromatid exchange in mouse splenocytes after exposure to the butadiene metabolite 3,4-epoxy-1-butene. Mutagenesis 12:425-429 (1997).
49.
Telentschak S, Soliwoda M, Nohroudi K, Addicks K, Klinz FJ: Cytokinesis failure and successful multipolar mitoses drive aneuploidy in glioblastoma cells. Oncol Rep 33:2001-2008 (2015).
50.
US-EPA: US Environmental Protection Agency: Health Assessment of 1,3-Butadiene. EPA/600/P-98/001F (National Center for Environmental Assessment, Washington 2002) http://www.epa.gov/ncea/.
51.
Vlachodimitropoulos D, Norppa H, Autio K, Catalán J, Hirvonen A, et al: GSTT1-dependent induction of centromere-negative and -positive micronuclei by 1,2:3,4-diepoxybutane in cultured human lymphocytes. Mutagenesis 12:397-403 (1997).
52.
Vock EH, Lutz WK, Ilinskaya O, Vamvakas S: Discrimination between genotoxicity and cytotoxicity for the induction of DNA double-strand breaks in cells treated with aldehydes and diepoxides. Mutat Res 441:85-93 (1999).
53.
Weaver BA, Cleveland DW: Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 67:10103-10105 (2007).
54.
Xi L, Zhang L, Wang Y, Smith MT: Induction of chromosome-specific aneuploidy and micronuclei in human lymphocytes by metabolites of 1,3-butadiene. Carcinogenesis 18:1687-1693 (1997).
55.
Xiang M, Ao L, Yang H, Liu W, Sun L, et al: Chromosomal damage and polymorphisms of metabolic genes among 1,3-butadiene-exposed workers in a matched study in China. Mutagenesis 27:415-421 (2012).
56.
Xiao Y, de Stoppelaar JM, Hoebee B, Schriever-Schwemmer G, Adler ID, Tates AD: Analysis of micronuclei induced by 1,3-butadiene and its metabolites using fluorescence in situ hybridization. Mutat Res 354:49-57 (1996).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.